Pregled bibliografske jedinice broj: 672244
Combining capecitabine and bevacizumab in metastatic breast cancer : a comprehensive review
Combining capecitabine and bevacizumab in metastatic breast cancer : a comprehensive review // European journal of cancer (1990), 48 (2012), 4; 482-491 doi:10.1016/j.ejca.2011.12.007 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 672244 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Combining capecitabine and bevacizumab in metastatic breast cancer : a comprehensive review
Autori
Miles, D. ; Zielinski, C. ; Martin, M. ; Vrdoljak, Eduard ; Robert, N.
Izvornik
European journal of cancer (1990) (0959-8049) 48
(2012), 4;
482-491
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
capecitabn; bevacizumab; metastatic breast cancer
Sažetak
Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited. We review available data on the capecitabine-bevacizumab combination in breast cancer, particularly results from the RIBBON-1 trial in the first-line setting, and we discuss these findings in light of previous studies. We also examine ongoing trials investigating capecitabine-bevacizumab combination therapy.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
216-0000000-0484 - Dvostruki model ovarijalne kancerogeneze - molekularna i morfološka studija (Tomić, Snježana, MZOS ) ( CroRIS)
Ustanove:
KBC Split,
Medicinski fakultet, Split
Profili:
Eduard Vrdoljak
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
